Research on the live, attenuated Mycobacterium TB vaccine, MTBVAC, in South African infants, appeared in The Lancet Respiratory Medicine journal this week.
This Phase 1b study, conducted in a TB endemic community, showed that vaccination of infants with MTBVAC displayed a similar safety profile and had indistinguishable reactions at the injection site to that of the current licensed TB vaccine, Bacille Calmette-Guérin (BCG), which has an excellent safety record.
Vaccination with MTBVAC induced a long-lasting immune response of greater magnitude than that of BCG at a comparable dose. This promising data supports further progression of MTBVAC through ongoing Phase 2a dose-defining studies and into large-scale infant efficacy trials.
Satvi director Professor Mark Hatherill said: “These exciting results are an important step towards a more effective TB vaccine, and support plans for a much larger trial to better define the safety and efficacy of MTBVAC in infants living in TB endemic countries.”